.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, individuals with metastatic stomach growths that acquired biomarker-matched therapies based on distributing cyst DNA profiling presented a higher medical perk than those acquiring unrivaled treatment.